Kymera Therapeutics

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial results on August 9,